Skip to main content
Premium Trial:

Request an Annual Quote

John Richert, Paul Wood, Ken Tindall, Nicholas Roelofs, Joseph Sorge, Janet Lankard, Paul Lucas, Neil Reid, Michael Mueller, Stevan Jovanovich, Scott Lockard, Arden Bement Jr., Rita Colwell, Michael Yeomans

John Richert has been named vice president of the business and technology development program at the North Carolina Biotechnology Center in Research Triangle Park. Richert, previously vice president of business development at Aeolus Pharmaceuticals, succeeds Paul Wood, who retired in August 2003. He will report to Ken Tindall, senior vice president for science and business development. Richert will oversee and manage the center’s loan programs, venture capital investments, and technology-transfer and business-development activities. Previously he was director of market development at Sphinx Pharmaceuticals in Durham, director of market development for new products at Schering-Plough in Kenilworth, NJ, and assistant product manager at Pfizer Laboratories in New York.

Nicholas Roelofs, chief operating officer for Stratagene, will resign effective Dec. 31, the company said last week in an SEC filing. Joseph Sorge, Stratagene’s CEO, will assume Roelofs’ responsibilities until a replacement hire is made, the company said.

Janet Lankard joins Quantum Dot of Hayward, Calif., to manage the company’s new sales team as vice president of sales, the company said last week. Lankard is the former director of sales for Affymetrix, where she was employed since 1998. Previously, she was executive sales account manager for Applied Biosystems, responsible for the Joint Genome Institute during the Human Genome project.

Paul Lucas was named chairman of the board; Neil Reid was appointed as vice-chairman; and Michael Mueller was named as a director of Tm Bioscience of Toronto, the company said last week. Lucas is the president and CEO of GlaxoSmithKline Canada and has been a director of Tm Bioscience since 2002. Reid, a co-founder of MDS Sciex and MDS Proteomics, has been a director of Tm Bioscience since 2000. He is a co-founder and is currently senior vice president of Protana. Previously, he was senior vice president of operations for MDS Proteomics and functioned as general manager of the Applied Biosystems/Sciex joint venture. Mueller is the president and CEO of MDS Capital and a member of its board.

Stevan Jovanovich, former vice president of global research at Amersham Biosciences, is president and CEO of Microchip Biotechnologies of Fremont, Calif., a startup that last month received a $6.1 million grant from NHGRI to develop a DNA sequencing technology.

Scott Lockard joins Menlo Park, Calif.-based ForteBio, formerly Aria Biosystems, as vice president of engineering, the company said last week. Lockard previously was a founder and vice president of engineering at Cell Biosciences. Before that he worked for Molecular Dynamics and Amersham Biosciences.

Arden Bement Jr., professor of nuclear engineering at Purdue University, has been appointed director of the National Science Foundation, replacing Rita Colwell, the agency said last month. Bement, on leave from Purdue, has served as director of the National Institute of Standards and Technology since December 2001. Bement will serve a six-year term as NSF director.

Michael Yeomans was named senior vice president for global business development for Biovail of Toronto, the company said this week. He will be based at the company’s offices in Bridgewater, NJ. Yeomans joins the company after serviing as SVP of global business development for Aventis Pharma.